# COVID-19 vaccination in Peru

The COVID-19 vaccination program in Peru is the national vaccination strategy to protect the population against SARS-CoV-2 employing vaccines developed for the COVID-19 pandemic in Peru. Vaccination began on 9 February 2021, after three days of arrival of first vaccines. On a nation message, the head of state Francisco Sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel.

## Timeline
### Arrival of the first vaccines

On 7 February 2021 at 19:54 h (UTC−5), 300,000 vaccines lot of Sinopharm coming from China arrived at the airport Jorge Chávez. This event was overseen by the president, Francisco Sagasti. Shortly after, the head of state reported that on 14 February a remaining lot 700,000 vaccines will also arrive to the country. On 8 February 2021, a thousand police officers were reported to guard the warehouse of National Center for the Supply of Strategic Health Resources (CENARES, acronym in Spanish).

## Vaccine distribution

According to the Government of Peru, the vaccination is predicted in three phases.
| Stage | People included |
| 1 | Health sector personnel National Police Armed Forces General Corps of Volunteer Firefighters Peruvian red cross Serenazgo (Watchman unit) Staff of the National Institute of Civil Defence (INDECI) Health-related science students. Board members of the 2021 national elections |
| 2 | People over 60 years and with comorbidity. Native or indigenous population Prison staff |
| 3 | People over 18 years of age |

## Public opinion

According to the study presented by IPSOS, a French sociological and market research company, the acceptance of the vaccine in the Peruvian population was below 50% until January 2021 due to an environment of mistrust in the management of the Vaccination and management of the pandemic during the government of Martín Vizcarra and Francisco Sagasti. As of February 2021, the period that begins the vaccination process, the study revealed a slow and steady increase in the acceptance of the COVID-19 vaccine.
Question: "Do you want to be vaccinated, do you not want to be vaccinated or have you already been vaccinated? :
| OptionMonth | I do want to get vaccinated | I don't want to get vaccinated | I already got vaccinated | Not precise |
| Aug 2020* | 75% | 22% | 0% | 3% |
| Dec 2020* | 57% | 40% | 0% | 3% |
| Jan 2021* | 48% | 48% | 0% | 4% |
| Feb 2021* | 59% | 35% | 0% | 6% |
| Mar 2021** | 60% | 33% | 0% | 7% |
| May 2021* | 63% | 30% | 4% | 3% |
Note: (*) It was asked how "If right now a vaccine approved by the Ministry of Health and free to prevent the COVID-19, do you? would you be vaccinated or not vaccinated? Note 2: (**) He wondered how "If tomorrow it's your turn for the COVID-19 vaccine, would you or would you not get the vaccine?"

## Vaccines on order

| Vaccine name | Doses | Progress | Quantity | Approval | Deployment | Last delivery |
| Sinopharm BIBP | Two | Phase III clinical trials | 6 million | 6 January 2021 | 7 February 2021 | 5 June 2021 |
| Pfizer–BioNTech | Two | Phase III clinical trials | 20,5 million | 9 February 2021 | 3 March 2021 | 1 July 2021 |
| Pfizer–BioNTech | Two | Phase III clinical trials | 12 million | 6 May 2021 | 3 March 2021 | 1 July 2021 |
| Pfizer–BioNTech | Two | Phase III clinical trials | 35 million | 17 September 2021 | 3 March 2021 | 1 July 2021 |
| Oxford–AstraZeneca and Pfizer–BioNTech (by Covax Facility) | Two | Phase III clinical trials | 13,2 million | 18 September 2020 | 10 March 2021 | 3 June 2021 |
| Oxford–AstraZeneca | Two | Phase III clinical trials | 14 million | 6 January 2021 | Not yet | Not yet |
| Johnson & Johnson | One | Phase III clinical trials | Pending | 8 July 2021 | Not yet | Not yet |
| Sputnik V | Two | Phase III clinical trials | 20 million | 20 July 2021 | Not yet | Not yet |
| Moderna | Two | Phase III clinical trials | 20 million | 17 September 2021 | Not yet | Not yet |
Chronology of the doses arrived in Peru :
| No. | Vaccine name | Quantity | Arrival date |
| 1 | Sinopharm BIBP | 300,000 | 7 February 2021 |
| 2 | Sinopharm BIBP | 700,000 | 13 February 2021 |
| 3 | Pfizer–BioNTech | 50,000 | 3 March 2021 |
| 4 | Pfizer–BioNTech (by Covax Facility) | 117,000 | 10 March 2021 |
| 5 | Pfizer–BioNTech | 50,000 | 10 March 2021 |
| 6 | Pfizer–BioNTech | 50,000 | 17 March 2021 |
| 7 | Pfizer–BioNTech | 50,310 | 24 March 2021 |
| 8 | Pfizer–BioNTech | 49,140 | 31 March 2021 |
| 9 | Pfizer–BioNTech | 200,070 | 7 April 2021 |
| 10 | Pfizer–BioNTech | 200,700 | 14 April 2021 |
| 11 | Oxford-AstraZeneca (by Covax Facility) | 276,000 | 18 April 2021 |
| 12 | Pfizer–BioNTech | 200,700 | 21 April 2021 |
| 13 | Pfizer–BioNTech | 200,000 | 28 April 2021 |
| 14 | Pfizer–BioNTech | 350,000 | 6 May 2021 |
| 15 | Pfizer–BioNTech | 350,000 | 7 May 2021 |
| 16 | Pfizer–BioNTech | 700,000 | 13 May 2021 |
| 17 | Pfizer–BioNTech | 395,000 | 17 May 2021 |
| 18 | Pfizer–BioNTech | 395,000 | 20 May 2021 |
| 19 | Pfizer–BioNTech | 396,630 | 24 May 2021 |
| 20 | Pfizer–BioNTech | 395,460 | 26 May 2021 |
| 21 | Oxford-AstraZeneca (by Covax Facility) | 511,200 | 29 May 2021 |
| 22 | Pfizer–BioNTech | 251,550 | 31 May 2021 |
| 23 | Sinopharm BIBP | 700,000 | 2 June 2021 |
| 24 | Pfizer–BioNTech (by Covax Facility) | 468,000 | 3 June 2021 |
| 25 | Pfizer–BioNTech | 250,380 | 3 June 2021 |
| 26 | Pfizer–BioNTech | 242,190 | 4 June 2021 |
| 27 | Sinopharm BIBP | 300,000 | 5 June 2021 |
| 28 | Pfizer–BioNTech | 496,080 | 10 June 2021 |
| 29 | Pfizer–BioNTech | 497,250 | 17 June 2021 |
| 30 | Pfizer–BioNTech | 497,250 | 24 June 2021 |
| 31 | Pfizer–BioNTech (United States donation) | 1,002,000 | 29 June 2021 |
| 32 | Pfizer–BioNTech | 497,250 | 1 July 2021 |
| 33 | Pfizer–BioNTech (United States donation) | 998,000 | 7 July 2021 |
| 34 | Sinopharm BIBP | 614,400 | 10 July 2021 |
| 35 | Sinopharm BIBP | 385,600 | 11 July 2021 |
| 36 | Pfizer–BioNTech | 281,970 | 15 July 2021 |
| 37 | Pfizer–BioNTech | 886,860 | 22 July 2021 |
| 38 | Pfizer–BioNTech | 936,000 | 26 July 2021 |
| 39 | Pfizer–BioNTech | 196,560 | 30 July 2021 |
| 40 | Sinopharm BIBP | 1,000,000 | 1 August 2021 |
| 41 | Oxford–AstraZeneca (Spain donation) | 101,760 | 4 August 2021 |
| 42 | Pfizer–BioNTech | 475,020 | 5 August 2021 |
| 43 | Pfizer–BioNTech | 569,790 | 12 August 2021 |
| 44 | Sinopharm BIBP | 1,000,000 | 15 August 2021 |
| 45 | Pfizer–BioNTech | 594,360 | 20 August 2021 |
| 46 | Sinopharm BIBP | 614,400 | 21 August 2021 |
| 47 | Sinopharm BIBP | 385,600 | 22 August 2021 |
| 48 | Pfizer–BioNTech | 540,540 | 26 August 2021 |
| 49 | Sinopharm BIBP | 1,000,000 | 29 August 2021 |
| 50 | Oxford–AstraZeneca (Canada donation) | 35,100 | 2 September 2021 |
| 51 | Pfizer–BioNTech | 662,220 | 3 September 2021 |
| 52 | Sinopharm BIBP | 2,000,000 | 4 September 2021 |
| 53 | Pfizer–BioNTech | 748,800 | 6 September 2021 |
| 54 | Oxford–AstraZeneca (by Covax Facility) | 362,400 | 8 September 2021 |
| 55 | Sinopharm BIBP | 2,862,500 | 10 September 2021 |
| 56 | Sinopharm BIBP | 3,342,600 | 11 September 2021 |
| 57 | Sinopharm BIBP | 794,900 | 12 September 2021 |
| 58 | Pfizer–BioNTech | 748,800 | 13 September 2021 |
| 59 | Oxford–AstraZeneca (Ecuador donation) | 336,000 | 13 September 2021 |
| 60 | Oxford–AstraZeneca (by Covax Facility) | 146,400 | 14 September 2021 |
Dose count and statistics :
| Vaccine name | Quantity | Total | % of population | % of population | Target population | % of population | % of population | Population (est. 2020) |
| Vaccine name | Quantity | Total | One dose | Two dose | Target population | One dose | Two dose | Population (est. 2020) |
| Sinopharm BIBP | 16,000,000 | 33,761,600 | 123.92% | 61.96% | 27,244,203 | 103.48% | 51.74% | 32,625,948 |
| Pfizer-BioNTech | 15,992,740 | 33,761,600 | 123.92% | 61.96% | 27,244,203 | 103.48% | 51.74% | 32,625,948 |
| Oxford-AstraZeneca | 1,768,860 | 33,761,600 | 123.92% | 61.96% | 27,244,203 | 103.48% | 51.74% | 32,625,948 |

## Vaccines in trial stage

| Vaccine | Type (technology) | Phase I | Phase II | Phase III |
| Sinopharm BIBP | Inactivated | Completed | Completed | Completed |
| Pfizer–BioNTech | RNA | Completed | Completed | Completed |
| Oxford–AstraZeneca | Viral vector | Completed | Completed | Completed |
| Janssen | Viral vector | Completed | Completed | In progress |
| CureVac | RNA | Completed | Completed | In progress |

## Statistics
### By department

COVID-19 vaccination by department September 15, 2021 (UTC−5) :
| Department and autonomous province | First dose | First dose | Second dose | Second dose | Cumulative dose | Population (est. 2020) |
| Department and autonomous province | Total | % of pop. | Total | % of pop. | Cumulative dose | Population (est. 2020) |
| Peru | 12,391,748 | 37.98% | 8,933,405 | 27.38% | 21,325,153 | 32,625,948 |
| Amazonas | 136,284 | 31.93% | 87,684 | 20.54% | 223,968 | 426,806 |
| Ancash | 462,904 | 39.21% | 335,213 | 28.39% | 798,117 | 1,180,638 |
| Apurimac | 173,013 | 40.17% | 109,310 | 25.38% | 282,323 | 430,736 |
| Arequipa | 631,543 | 42.17% | 461,804 | 30.84% | 1,093,347 | 1,497,438 |
| Ayacucho | 213,214 | 31.91% | 132,005 | 19.75% | 345,219 | 668,213 |
| Cajamarca | 476,824 | 32.80% | 318,320 | 21.90% | 795,144 | 1,453,711 |
| Callao province | 579,182 | 51.26% | 435,523 | 38.55% | 1,014,705 | 1,129,854 |
| Cusco | 444,355 | 32.74% | 333,979 | 24.61% | 778,334 | 1,357,075 |
| Huancavelica | 127,322 | 34.85% | 94,532 | 25.88% | 221,854 | 365,317 |
| Huanuco | 206,599 | 27.17% | 128,563 | 16.91% | 335,162 | 760,267 |
| Ica | 400,451 | 41.06% | 265,235 | 27.20% | 665,686 | 975,182 |
| Junin | 508,964 | 37.38% | 397,651 | 29.21% | 906,615 | 1,361,467 |
| La Libertad | 661,806 | 32.82% | 443,839 | 22.01% | 1,105,645 | 2,016,771 |
| Lambayeque | 386,439 | 29.48% | 277,086 | 21.14% | 663,525 | 1,310,785 |
| Lima | 444,891 | 46.65% | 295,779 | 31.01% | 740,670 | 953,715 |
| Lima province | 4,456,211 | 46.06% | 3,425,830 | 35.41% | 7,882,041 | 9,674,755 |
| Loreto | 215,317 | 20.95% | 147,365 | 14.34% | 362,682 | 1,027,559 |
| Madre de Dios | 40,197 | 23.13% | 26,153 | 15.05% | 66,350 | 173,811 |
| Moquegua | 80,252 | 41.64% | 61,156 | 31.73% | 141,408 | 192,740 |
| Pasco | 112,817 | 41.49% | 81,992 | 30.15% | 194,809 | 271,904 |
| Piura | 625,908 | 30.56% | 422,917 | 20.65% | 1,048,825 | 2,047,954 |
| Puno | 274,952 | 22.21% | 150,940 | 12.19% | 425,892 | 1,237,997 |
| San Martin | 281,842 | 31.33% | 189,418 | 21.05% | 471,260 | 899,648 |
| Tacna | 198,557 | 53.52% | 147,786 | 39.84% | 346,343 | 370,974 |
| Tumbes | 93,790 | 37.29% | 58,474 | 23.25% | 152,264 | 251,521 |
| Ucayali | 158,114 | 26.84% | 104,851 | 17.80% | 262,965 | 589,110 |

### Progress of the vaccination campaign

COVID-19 vaccination progress in Peru Estimated population to be vaccinated: 27,244,203 people
45.5% complete
(Inoculated with first dose)
32.8% complete
(Inoculated with second dose) :
| Date | First dose | First dose | First dose | Second dose | Second dose | Second dose | Cumulative dose |
| Date | Total | Variation | % of pop. | Total | Variation | % of pop. | Cumulative dose |
| 9-feb-21 | 3,842 | 3,842 | 0.01% | 0 | 0 | 0.00% | 3,842 |
| 15-feb-21 | 110,792 | 106,950 | 0.41% | 0 | 0 | 0.00% | 110,792 |
| 1-mar-21 | 321,851 | 211,059 | 1.18% | 0 | 0 | 0.00% | 321,851 |
| 15-mar-21 | 430,874 | 109,023 | 1.58% | 173,578 | 173,578 | 0.64% | 604,452 |
| 1-apr-21 | 662,463 | 231,589 | 2.43% | 377,945 | 204,367 | 1.39% | 1,040,408 |
| 15-abr-21 | 743,077 | 80,614 | 2.73% | 544,887 | 166,942 | 2.00% | 1,287,964 |
| 1-may-21 | 1,127,587 | 384,510 | 4.14% | 687,606 | 142,719 | 2.52% | 1,815,193 |
| 15-may-21 | 1,815,080 | 687,493 | 6.66% | 825,828 | 138,222 | 3.03% | 2,640,908 |
| 1-jun-21 | 2,984,620 | 1,169,540 | 10.96% | 1,332,284 | 506,456 | 4.89% | 4,316,904 |
| 15-jun-21 | 3,829,456 | 844,836 | 14.06% | 2,236,998 | 904,714 | 8.21% | 6,066,454 |
| 1-Jul-21 | 4,612,161 | 782,705 | 16.93% | 3,287,742 | 1,050,744 | 12.07% | 7,899,903 |
| 15-jul-21 | 6,474,729 | 1,862,568 | 23.77% | 3,845,047 | 557,305 | 14.11% | 10,319,776 |
| 1-aug-21 | 8,035,796 | 1,561,067 | 29.50% | 5,287,167 | 1,442,120 | 19.41% | 13,322,963 |
| 15-aug-21 | 9,215,626 | 1,023,435 | 33.83% | 6,920,113 | 1,437,778 | 25.40% | 16,135,739 |
| 1-sep-21 | 10,519,572 | 1,184,432 | 38.61% | 8,314,606 | 1,191,212 | 30.52% | 18,834,178 |
| 15-sep-21 | 12,391,748 | 1,747,180 | 45.48% | 8,933,405 | 495,538 | 32.79% | 21,325,153 |

### Demographics

Vaccination by sex and age, registered on September 15, 2021 :
| Year group | Male | Male | Female | Female | First dose | First dose | Second dose | Second dose | Cumulative dose | Population (est. 2020) |
| Year group | One dose | Two dose | One dose | Two dose | Total | % of pop. | Total | % of pop. | Cumulative dose | Population (est. 2020) |
| Total | 5,883,925 | 4,205,383 | 6,507,830 | 4,728,027 | 12,391,755 | 37.98% | 8,933,410 | 27.38% | 21,325,165 | 32,625,948 |
| 0-9 | 0 | 0 | 0 | 0 | 0 | 0.00% | 0 | 0.00% | 0 | 5,384,070 |
| 10-19 | 1 | 2 | 1 | 2 | 2 | 0.00% | 4 | 0.00% | 6 | 5,206,372 |
| 20-29 | 268,104 | 165,164 | 276,265 | 147,666 | 544,369 | 10.07% | 312,830 | 5.79% | 857,199 | 5,403,670 |
| 30-39 | 902,481 | 227,252 | 1,048,431 | 295,265 | 1,950,912 | 38.78% | 522,517 | 10.39% | 2,473,429 | 5,031,117 |
| 40-49 | 1,469,356 | 916,504 | 1,618,837 | 1,057,378 | 3,088,193 | 73.82% | 1,973,882 | 47.19% | 5,062,075 | 4,183,147 |
| 50-59 | 1,323,836 | 1,122,048 | 1,433,083 | 1,243,231 | 2,756,919 | 84.13% | 2,365,279 | 72.18% | 5,122,198 | 3,277,134 |
| 60-69 | 991,384 | 906,676 | 1,065,272 | 983,839 | 2,056,656 | 92.59% | 1,890,515 | 85.11% | 3,947,171 | 2,221,241 |
| 70-79 | 598,883 | 560,388 | 653,300 | 614,198 | 1,252,183 | 98.45% | 1,174,586 | 92.35% | 2,426,769 | 1,271,842 |
| 80+ | 329,878 | 307,348 | 412,638 | 386,448 | 742,516 | 114.70% | 693,796 | 107.17% | 1,436,312 | 647,355 |
| No data | 2 | 1 | 3 | 0 | 5 | - | 1 | - | 6 | - |

### Graphs
#### Departments by type of vaccines

* Last updated: September 15, 2021.
Data source: Platform of "Datos abiertos", Government of Peru.

#### Inoculated doses in provinces

* Last updated: September 15, 2021.
Percentage of population (2020) with second dose in most populated provinces of the country.
Note: Name of provinces and department name in parentheses. Chiclayo (Lambayeque), Coronel Portillo (Ucayali), Huancayo (Junin), Lima (Lima province), Maynas (Loreto), Santa (Ancash) and Trujillo (La Libertad) Data source: Platform of "Datos abiertos", Government of Peru.

#### Districts of Lima with the most vaccinations

* Last updated: September 15, 2021.
Districts of the city of Lima with the highest reception of people who were inoculated with the two doses with respect to the size of their population (est. 2020). The districts with the highest percentage vaccinate people who come from other districts and have large vaccination centers.
Data source: Platform of "Datos abiertos", Government of Peru.

#### Vaccine distribution

* Last updated: September 15, 2021.
Data source: Platform of "Datos abiertos", Government of Peru.

#### Vaccination progress

* Last updated: September 15, 2021.
Data source: Platform of "Datos abiertos", Government of Peru.